GlaxoSmithKline has released an open platform for clinical trial publication in a bid to display increased transparency.

Scientists will be able to request anonymised drug trial data, with the request being judged by a panel, which will give approval on a cases by case basis.

The move to provide data, regardless of the trial’s success or failure, combats repeated criticism made against the pharmaceutical sector, including artificially skewering results by only publishing successful trials.

GSK CEO Andrew Witty, said back in October 2012, when the scheme was first announced: “We hear from the scientific community that making this information available for valid scientific purposes will be incredibly helpful”.

GSK make £1.6bn hostile bid

GlaxoSmithKline chooses cloud-based digital marketing platform from Infosys